CELC

Celcuity is a textbook single-asset clinical-stage biotech: per the 10-K, it 'has not yet commercialized a pharmaceutical product' and since inception in January 2012 has 'had no revenue.' The entire equity value rests on gedatolisib, a pan-class I PI3K plus mTORC1/2 inhibitor licensed from Pfizer in April 2021, now in two Phase 3 trials (VIKTORIA-1 in HR+/HER2- advanced breast cancer, where cohort 1 PIK3CA-WT has 'reported detailed results' and cohort 2 PIK3CA-MT has 'completed enrollment') and Phase 1b/2 CELC-G-201 in mCRPC. Management's pitch — pan-isoform PI3K + mTORC1/2 inhibition avoiding the feedback-loop resistance and the hyperglycemia/rash/diarrhea toxicity that derailed alpelisib (39% Grade 3/4 hyperglycemia, 26% discontinuation in the PIQRAY pivotal) — is mechanistically credible and is the differentiator that justifies the +6.84% reaction today.

The numbers fit the story but underline the risk. FY2025 net loss widened 58% to -$177M with operating losses of -$172M, R&D up 39% to $145M as Phase 3 spending peaks, and operating cash burn hit -$153M. Critically, the balance sheet was reloaded: cash went from $23M to $166M (+636%), total assets +90% to $467M, while long-term debt rose 31% to $138M and share count grew 28% to 48.3M — i.e., they raised both equity and debt to fund through readout. Liabilities/equity at 3.64x and accumulated deficit of -$449M look ugly but are normal for a Phase 3 biotech; what matters is that current assets ($466M) vastly exceed current liabilities ($44M), giving roughly a year of runway at the current burn rate before the next financing.